Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
MyCelx reports decent progress across business
(Sharecast News) - Clean water and air technology specialist MyCelx Technologies said in an update on Wednesday that, following the successful sale of its Saudi Arabian business operations in the first quarter, it had redirected internal resources towards advancing its marketing and sales plan for its technologies in the PFAS remediation and enhanced oil recovery (EOR) markets. The AIM-traded firm said that in the United States, it had successfully completed a treatability study, paving the way for participation in a four-month pilot trial treating PFAS contamination at a municipal wastewater treatment facility, expected to start in the first quarter of 2025.
Additionally, it said it was conducting a short-term emergency PFAS remediation project at a refinery, aiming to expand Aqueous Film Forming Foam (AFFF) clean-up projects globally.
Moreover, MyCelx said it was engaged in pre-treatment system identification for a landfill leachate project and ramping up rapid small scale column tests for PFAS water characterisation and removal.
On the commercial and strategic front, MyCelx said it anticipated finalising an agreement with a US-based water system supplier to integrate its PFAS media into their product line.#
It said it was also pursuing discussions with potential partners in PFAS target markets and recently hired a technical expert with nine years of PFAS experience.
In Australia, MyCelx reported increased sales of PFAS systems by its Australian distribution partner, with recent successes in liquid waste facility and engineering firm projects.
In the realm of REGEN for EOR and beneficial reuse, MyCelx said it was running a pilot with a global energy technology company in the Middle East to showcase REGEN media's capabilities.
Additionally, the company said it was commencing a REGEN pilot trial in Canada with an EOR producer.
On the commercial and strategic front for REGEN, MyCelx said it delivered the first REGEN retrofit package to a Middle Eastern EOR customer and received notification from a global product supplier favouring REGEN technology for EOR produced water treatment.
The company also strengthened the REGEN team with the addition of an experienced engineer.
"We continue to be upbeat about the progress we have made in 2024 and the outlined developments mentioned reinforce the significant advancements we are making as a business," said chief executive officer Connie Mixon.
"We intend to capitalise on positive recent developments in the US, following the publishing of the EPA PFAS Drinking Water regulations, and we continue to aggressively pursue partnerships, pilots, data collection and projects in our core markets.
"There is tremendous opportunity in the EOR market for our REGEN product."
Mixon said the company was engaged with multiple producers who required better performance and a reliable solution to water management during production for EOR and beneficial reuse.
"Both our PFAS and REGEN offerings are designed to be best in class in their applications and we expect to see a continued uptick in demand for sales and/or pilot projects from globally recognisable firms over the rest of 2024."
At 0850 BST, shares in MyCelx Technologies Corporation were up 4.44% at 57.44p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.